Adenine arabinoside monophosphate coupled to lactosaminated human albumin administered for 4 weeks in patients with chronic type B hepatitis decreased viremia without producing significant side effects
M T Cerenzia, L Fiume, W De Bernardi Venon, B Lavezzo, M R Brunetto, A Ponzetto, G Di Stefano, C Busi, A Mattioli, G B Gervasi, F Bonino, G Verme – 1 April 1996 – A conjugate of adenine arabinoside monophosphate (ara‐AMP) with the liver‐targeting molecule lactosaminated human serum albumin (L‐HSA) was administered by intravenous infusion for 28 days to eight patients with chronic type B hepatitis. The daily dose varied among the patients, ranging from 34 mg/kg to 53 mg/kg (equal to 1.5 and 2.3 mg/kg ara‐AMP, respectively).